The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
1 天
Pharmaceutical Technology on MSNGalderma enters fierce European atopic dermatitis market with Nemluvio approvalNemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
These drugs inhibit interleukin (IL)-5, while Dupixent inhibits IL-4 and IL-13, but can be considered a rival because it is also an injection. Patients may opt to take the others because of their ...
Dupixent was cleared by the US FDA for adults with PN in September, making it an option for an estimated 75,000 patients with the condition, and adding to the drug's earlier approvals in atopic ...
Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...
(NASDAQ:REGN) succeeded in taking the fight to Roche by decreasing the number of annual injections. The company’s other growth driver, Dupixent, is also doing well, helping shrug off sales ...
Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果